FXR, a therapeutic target for bile acid and lipid disorders
- PMID: 16101408
- DOI: 10.2174/1389557054553802
FXR, a therapeutic target for bile acid and lipid disorders
Abstract
The farnesoid X receptor (FXR) is a nuclear receptor expressed in tissues exposed to high concentrations of bile acids such as the liver, kidney and intestine and functions as a bile acid sensor. FXR regulates the expression of various transport proteins and biosynthetic enzymes crucial to the physiological maintenance of lipids, cholesterol and bile acid homeostasis. The concept of reverse endocrinology, whereby the receptor is identified first, followed by the identification of ligands and the sequential elucidation of the physiological role of the receptor has been widely used for a number of orphan nuclear receptors. The design of synthetic high affinity ligands acting via these receptors not only helps to decipher the function of the receptor, but also should lead to the development of novel and highly specific drugs. The bile acid receptor FXR is a perfect example where this strategy helped with understanding the role of this receptor in cholesterol and bile acid homeostasis. Regulation of FXR through small-molecule drugs represents a promising therapy for diseases resulting from lipid, cholesterol and bile acid abnormalities.
Similar articles
-
The role of the enterohepatic circulation of bile salts and nuclear hormone receptors in the regulation of cholesterol homeostasis: Bile salts as ligands for nuclear hormone receptors.Can J Gastroenterol. 2003 Apr;17(4):265-71. doi: 10.1155/2003/190784. Can J Gastroenterol. 2003. PMID: 12704471 Review.
-
FXR, a target for different diseases.Histol Histopathol. 2008 May;23(5):621-7. doi: 10.14670/HH-23.621. Histol Histopathol. 2008. PMID: 18283647 Review.
-
Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor.Mol Endocrinol. 2003 Feb;17(2):259-72. doi: 10.1210/me.2002-0120. Mol Endocrinol. 2003. PMID: 12554753
-
Targeting farnesoid X receptor for liver and metabolic disorders.Trends Mol Med. 2007 Jul;13(7):298-309. doi: 10.1016/j.molmed.2007.06.001. Epub 2007 Jun 27. Trends Mol Med. 2007. PMID: 17588816 Review.
-
FXR: a promising target for the metabolic syndrome?Trends Pharmacol Sci. 2007 May;28(5):236-43. doi: 10.1016/j.tips.2007.03.002. Epub 2007 Apr 6. Trends Pharmacol Sci. 2007. PMID: 17412431 Review.
Cited by
-
Nuclear receptors as therapeutic targets in cholestatic liver diseases.Br J Pharmacol. 2009 Jan;156(1):7-27. doi: 10.1111/j.1476-5381.2008.00030.x. Br J Pharmacol. 2009. PMID: 19133988 Free PMC article. Review.
-
Silymarin Ameliorates Metabolic Dysfunction Associated with Diet-Induced Obesity via Activation of Farnesyl X Receptor.Front Pharmacol. 2016 Sep 28;7:345. doi: 10.3389/fphar.2016.00345. eCollection 2016. Front Pharmacol. 2016. PMID: 27733832 Free PMC article.
-
Altered systemic bile acid homeostasis contributes to liver disease in pediatric patients with intestinal failure.Sci Rep. 2016 Dec 15;6:39264. doi: 10.1038/srep39264. Sci Rep. 2016. PMID: 27976737 Free PMC article.
-
Gut macrobiotic and its metabolic pathways modulate cardiovascular disease.Front Microbiol. 2023 Sep 26;14:1272479. doi: 10.3389/fmicb.2023.1272479. eCollection 2023. Front Microbiol. 2023. PMID: 37822750 Free PMC article. Review.
-
The farnesoid X receptor regulates transcription of 3beta-hydroxysteroid dehydrogenase type 2 in human adrenal cells.Mol Cell Endocrinol. 2009 Feb 27;299(2):153-62. doi: 10.1016/j.mce.2008.11.006. Epub 2008 Nov 18. Mol Cell Endocrinol. 2009. PMID: 19059462 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical